{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.0009","statisticalMethod":"Wilcoxon signed rank test"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.40","statisticalMethod":"Wilcoxon signed rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.9","value":"-2.7"},{"groupId":"OG001","spread":"1.0","value":"-1.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"299"}],"units":"Participants"}],"description":"The primary QOL change was evaluated by the Functional Assessment of Cancer Therapy - Prostate (FACT-P) instrument. FACT-P is a self-report measure of both general and disease-specific QOL. Higher scores represent better QOL. The FACT-P (version 4) contains 39 likert items distributed over 5 subscales: physical (7 items), social/family (7 items), emotional (6 items), and functional (7 items) well-being, and the additional concerns related to prostate cancer scale (12 items). The FACT-P total score is calculated by summing all these 5 subscales and ranges from 0 to 156.","dispersionType":"Standard Error","groups":[{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Androgen-Deprivation Therapy and Docetaxel"},{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration).","id":"OG001","title":"Androgen-Deprivation Therapy Alone"}],"paramType":"MEAN","populationDescription":"Patients with both baseline and 3-month QOL assessments are included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed at baseline and 3 months","title":"QOL Change From Baseline to 3 Months","type":"SECONDARY","unitOfMeasure":"units on a scale"}